Nonsteroidal selective androgen receptor modulator · Fact sheet
Andarine
Also known as S-4 · GTx-007
Andarine is an unapproved SARM encountered in analytical and doping-control studies. Those studies identify exposure; they do not establish a safe human muscle-growth or fat-loss regimen.
What is Andarine?
The S-4 identifier refers to a distinct arylpropionamide SARM.
Chemical detection in a product or urine sample is different from a controlled efficacy trial.
Benefits & claims
Interest includes performance or metabolic effects, but a mechanism, hormone change or lean-mass result does not establish safe improvement in athletic function.
What the evidence supports
- Analytical studies identify andarine in products and biological samples.
- Those findings confirm that exposure occurs, not that advertised performance benefits are real.
- A compound-specific human efficacy or dosing claim is not supported by these sources.
Research areas
- Performance-related biology
- Clinical or preclinical disease research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Andarine. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The S-4 identifier refers to a distinct arylpropionamide SARM.
Formulation differences
- Chemical detection in a product or urine sample is different from a controlled efficacy trial.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Side effects & risks
- FDA SARM warnings include serious liver, cardiovascular and hormonal risks; exact andarine incidence is unknown.
- Product identity, prolonged endocrine effects and visual complaints require direct clinical assessment rather than assuming tissue selectivity guarantees safety.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe cited sources characterize products and metabolites. They do not supply reliable controlled human functional or long-term safety outcomes.
Studies
Chemical identification in a nonstandard product.
Urinary-metabolite characterization for detection.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Andarine has no FDA-approved therapeutic product. The cited research does not establish an approved performance-enhancement use.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product.
- Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes.
- FDA: serious risks of SARM bodybuilding products
Open questions
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Summary
A compound-specific human efficacy or dosing claim is not supported by these sources.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedDetection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product.
Chemical identification in a nonstandard product.
- pubmedMass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes.
Urinary-metabolite characterization for detection.
- fdaFDA: serious risks of SARM bodybuilding products
FDA class-level warning: unapproved products, liver injury and cardiovascular and hormone-associated risks; not a compound-specific incidence estimate.